Lataa...
Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
BACKGROUND: The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with significant toxicity. METHODS: Patients with MDR-TB treated at our institution receive amikacin at 8–10 mg/kg, with dose adjustment b...
Tallennettuna:
| Julkaisussa: | BMC Infect Dis |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7945371/ https://ncbi.nlm.nih.gov/pubmed/33691624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-021-05947-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|